Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in connect MM

Sundar Jagannath, Rafat Abonour, Brian G.M. Durie, Mohit Narang, Howard R. Terebelo, Cristina J. Gasparetto, Kathleen Toomey, James W. Hardin, Lynne Wagner, Amit Agarwal, Shankar Srinivasan, Amani Kitali, E. Dawn Flick, Michael Sturniolo, Robert M. Rifkin

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Autologous stem cell transplantation (ASCT) followed by lenalidomide maintenance therapy is the standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). Clinical trials show progression-free survival (PFS) benefits, with some studies (Cancer and Leukemia Group [CALGB] trial and meta-analysis) also showing overall survival (OS) benefits, but applicability to real-world clinical settings is unclear. Using data from Connect MM, the largest US-based observational registry of NDMM patients, we analyzed effects of maintenance therapy on long-term outcomes in 1450 treated patients enrolled from 2009 to 2011. Patients who received induction therapy and ASCT (n 5 432) were analyzed from 100 days post-ASCT (data cut 7 January 2016): 267 received maintenance (80% lenalidomide-based [of whom 88% received lenalidomide monotherapy]); 165 did not. Lenalidomide maintenance improved median PFS and 3-year PFS rate vs no maintenance (50.3 vs 30.8 months [hazard ratio (HR), 0.62; 95% confidence interval (CI), 0.46-0.82; P, .001] and 56% vs 42%, respectively). Improvements in median OS and 3-year OS rate were associated with lenalidomide maintenance vs no maintenance (not reached in either group [HR, 0.54; 95% CI, 0.36-0.83; P 5 .005] and 85% vs 70%, respectively). Five hematologic serious adverse events were reported with lenalidomide maintenance (pancytopenia [n 5 2], febrile neutropenia, anemia, and thrombocytopenia [n 5 1 each]) and 1 with no maintenance (thrombocytopenia). Second primary malignancies occurred at rates of 1.38 and 2.19 events per patient-year in lenalidomide maintenance and no maintenance groups, respectively. Survival benefits associated with lenalidomide maintenance previously demonstrated in clinical trials were observed in this community-based Connect MM Registry.

Original languageEnglish (US)
Pages (from-to)1608-1615
Number of pages8
JournalBlood Advances
Volume2
Issue number13
DOIs
StatePublished - Jul 10 2018
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Multiple Myeloma
Maintenance
Disease-Free Survival
Therapeutics
Thrombocytopenia
Survival
Registries
Survival Rate
Clinical Trials
Confidence Intervals
Febrile Neutropenia
Pancytopenia
Second Primary Neoplasms
lenalidomide
Standard of Care
Meta-Analysis
Anemia
Leukemia
Transplants

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Jagannath, S., Abonour, R., Durie, B. G. M., Narang, M., Terebelo, H. R., Gasparetto, C. J., ... Rifkin, R. M. (2018). Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in connect MM. Blood Advances, 2(13), 1608-1615. https://doi.org/10.1182/bloodadvances.2018017186

Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in connect MM. / Jagannath, Sundar; Abonour, Rafat; Durie, Brian G.M.; Narang, Mohit; Terebelo, Howard R.; Gasparetto, Cristina J.; Toomey, Kathleen; Hardin, James W.; Wagner, Lynne; Agarwal, Amit; Srinivasan, Shankar; Kitali, Amani; Dawn Flick, E.; Sturniolo, Michael; Rifkin, Robert M.

In: Blood Advances, Vol. 2, No. 13, 10.07.2018, p. 1608-1615.

Research output: Contribution to journalArticle

Jagannath, S, Abonour, R, Durie, BGM, Narang, M, Terebelo, HR, Gasparetto, CJ, Toomey, K, Hardin, JW, Wagner, L, Agarwal, A, Srinivasan, S, Kitali, A, Dawn Flick, E, Sturniolo, M & Rifkin, RM 2018, 'Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in connect MM', Blood Advances, vol. 2, no. 13, pp. 1608-1615. https://doi.org/10.1182/bloodadvances.2018017186
Jagannath, Sundar ; Abonour, Rafat ; Durie, Brian G.M. ; Narang, Mohit ; Terebelo, Howard R. ; Gasparetto, Cristina J. ; Toomey, Kathleen ; Hardin, James W. ; Wagner, Lynne ; Agarwal, Amit ; Srinivasan, Shankar ; Kitali, Amani ; Dawn Flick, E. ; Sturniolo, Michael ; Rifkin, Robert M. / Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in connect MM. In: Blood Advances. 2018 ; Vol. 2, No. 13. pp. 1608-1615.
@article{c56aff89bb1443659469c3979cfcf08a,
title = "Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in connect MM",
abstract = "Autologous stem cell transplantation (ASCT) followed by lenalidomide maintenance therapy is the standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). Clinical trials show progression-free survival (PFS) benefits, with some studies (Cancer and Leukemia Group [CALGB] trial and meta-analysis) also showing overall survival (OS) benefits, but applicability to real-world clinical settings is unclear. Using data from Connect MM, the largest US-based observational registry of NDMM patients, we analyzed effects of maintenance therapy on long-term outcomes in 1450 treated patients enrolled from 2009 to 2011. Patients who received induction therapy and ASCT (n 5 432) were analyzed from 100 days post-ASCT (data cut 7 January 2016): 267 received maintenance (80{\%} lenalidomide-based [of whom 88{\%} received lenalidomide monotherapy]); 165 did not. Lenalidomide maintenance improved median PFS and 3-year PFS rate vs no maintenance (50.3 vs 30.8 months [hazard ratio (HR), 0.62; 95{\%} confidence interval (CI), 0.46-0.82; P, .001] and 56{\%} vs 42{\%}, respectively). Improvements in median OS and 3-year OS rate were associated with lenalidomide maintenance vs no maintenance (not reached in either group [HR, 0.54; 95{\%} CI, 0.36-0.83; P 5 .005] and 85{\%} vs 70{\%}, respectively). Five hematologic serious adverse events were reported with lenalidomide maintenance (pancytopenia [n 5 2], febrile neutropenia, anemia, and thrombocytopenia [n 5 1 each]) and 1 with no maintenance (thrombocytopenia). Second primary malignancies occurred at rates of 1.38 and 2.19 events per patient-year in lenalidomide maintenance and no maintenance groups, respectively. Survival benefits associated with lenalidomide maintenance previously demonstrated in clinical trials were observed in this community-based Connect MM Registry.",
author = "Sundar Jagannath and Rafat Abonour and Durie, {Brian G.M.} and Mohit Narang and Terebelo, {Howard R.} and Gasparetto, {Cristina J.} and Kathleen Toomey and Hardin, {James W.} and Lynne Wagner and Amit Agarwal and Shankar Srinivasan and Amani Kitali and {Dawn Flick}, E. and Michael Sturniolo and Rifkin, {Robert M.}",
year = "2018",
month = "7",
day = "10",
doi = "10.1182/bloodadvances.2018017186",
language = "English (US)",
volume = "2",
pages = "1608--1615",
journal = "Blood advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "13",

}

TY - JOUR

T1 - Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in connect MM

AU - Jagannath, Sundar

AU - Abonour, Rafat

AU - Durie, Brian G.M.

AU - Narang, Mohit

AU - Terebelo, Howard R.

AU - Gasparetto, Cristina J.

AU - Toomey, Kathleen

AU - Hardin, James W.

AU - Wagner, Lynne

AU - Agarwal, Amit

AU - Srinivasan, Shankar

AU - Kitali, Amani

AU - Dawn Flick, E.

AU - Sturniolo, Michael

AU - Rifkin, Robert M.

PY - 2018/7/10

Y1 - 2018/7/10

N2 - Autologous stem cell transplantation (ASCT) followed by lenalidomide maintenance therapy is the standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). Clinical trials show progression-free survival (PFS) benefits, with some studies (Cancer and Leukemia Group [CALGB] trial and meta-analysis) also showing overall survival (OS) benefits, but applicability to real-world clinical settings is unclear. Using data from Connect MM, the largest US-based observational registry of NDMM patients, we analyzed effects of maintenance therapy on long-term outcomes in 1450 treated patients enrolled from 2009 to 2011. Patients who received induction therapy and ASCT (n 5 432) were analyzed from 100 days post-ASCT (data cut 7 January 2016): 267 received maintenance (80% lenalidomide-based [of whom 88% received lenalidomide monotherapy]); 165 did not. Lenalidomide maintenance improved median PFS and 3-year PFS rate vs no maintenance (50.3 vs 30.8 months [hazard ratio (HR), 0.62; 95% confidence interval (CI), 0.46-0.82; P, .001] and 56% vs 42%, respectively). Improvements in median OS and 3-year OS rate were associated with lenalidomide maintenance vs no maintenance (not reached in either group [HR, 0.54; 95% CI, 0.36-0.83; P 5 .005] and 85% vs 70%, respectively). Five hematologic serious adverse events were reported with lenalidomide maintenance (pancytopenia [n 5 2], febrile neutropenia, anemia, and thrombocytopenia [n 5 1 each]) and 1 with no maintenance (thrombocytopenia). Second primary malignancies occurred at rates of 1.38 and 2.19 events per patient-year in lenalidomide maintenance and no maintenance groups, respectively. Survival benefits associated with lenalidomide maintenance previously demonstrated in clinical trials were observed in this community-based Connect MM Registry.

AB - Autologous stem cell transplantation (ASCT) followed by lenalidomide maintenance therapy is the standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). Clinical trials show progression-free survival (PFS) benefits, with some studies (Cancer and Leukemia Group [CALGB] trial and meta-analysis) also showing overall survival (OS) benefits, but applicability to real-world clinical settings is unclear. Using data from Connect MM, the largest US-based observational registry of NDMM patients, we analyzed effects of maintenance therapy on long-term outcomes in 1450 treated patients enrolled from 2009 to 2011. Patients who received induction therapy and ASCT (n 5 432) were analyzed from 100 days post-ASCT (data cut 7 January 2016): 267 received maintenance (80% lenalidomide-based [of whom 88% received lenalidomide monotherapy]); 165 did not. Lenalidomide maintenance improved median PFS and 3-year PFS rate vs no maintenance (50.3 vs 30.8 months [hazard ratio (HR), 0.62; 95% confidence interval (CI), 0.46-0.82; P, .001] and 56% vs 42%, respectively). Improvements in median OS and 3-year OS rate were associated with lenalidomide maintenance vs no maintenance (not reached in either group [HR, 0.54; 95% CI, 0.36-0.83; P 5 .005] and 85% vs 70%, respectively). Five hematologic serious adverse events were reported with lenalidomide maintenance (pancytopenia [n 5 2], febrile neutropenia, anemia, and thrombocytopenia [n 5 1 each]) and 1 with no maintenance (thrombocytopenia). Second primary malignancies occurred at rates of 1.38 and 2.19 events per patient-year in lenalidomide maintenance and no maintenance groups, respectively. Survival benefits associated with lenalidomide maintenance previously demonstrated in clinical trials were observed in this community-based Connect MM Registry.

UR - http://www.scopus.com/inward/record.url?scp=85057967888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057967888&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2018017186

DO - 10.1182/bloodadvances.2018017186

M3 - Article

C2 - 29986853

AN - SCOPUS:85057967888

VL - 2

SP - 1608

EP - 1615

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 13

ER -